Orion Pharma Announces First Results from Phase 1/2 TEADES Trial with ODM-212

Orion Pharma's ODM-212 Shows Early Efficacy in Advanced Solid Tumours

Orion Pharma announced the first Phase 1 results from its ongoing Phase 1/2 TEADES trial, evaluating the oral pan-TEAD inhibitor ODM-212 in patients with advanced solid tumours. Presented at the 2026 ASCO Annual Meeting, the data showed ODM-212 was well tolerated, with proteinuria (19.7%) as the most common treatment-related adverse event. Early efficacy signals were observed, particularly in mesothelioma, achieving an overall response rate (ORR) of 27.8% and a disease control rate (DCR) of 77.8%, and in epithelioid hemangioendothelioma (EHE) with an ORR of 22.2% and DCR of 100%. These positive results support the continued clinical development of ODM-212.

• ODM-212 demonstrated a favorable safety profile in the Phase 1 portion of the TEADES trial. No dose-limiting toxicities were reported, and the maximum tolerated dose was not reached. The most frequent treatment-related adverse event was proteinuria (19.7%), which was reversible and manageable, leading to treatment adjustment in 7.9% of patients. Other common TRAEs included increased lipase (15.8%) and nausea (10.5%), indicating a generally well-tolerated profile for the investigational drug.
• The trial showed encouraging early signs of clinical activity, particularly in specific tumour types with Hippo pathway dysregulation. In mesothelioma, ODM-212 achieved an overall response rate (ORR) of 27.8% and a disease control rate (DCR) of 77.8%. For epithelioid hemangioendothelioma (EHE), the ORR was 22.2% and the DCR was 100%. These results highlight ODM-212's potential in areas with limited treatment options and support its targeted mechanism of action.
• Building on these positive Phase 1 results, the TEADES trial is progressing into Phase 2, aiming to enroll up to 300 patients with malignant pleural mesothelioma, EHE, or other solid tumours with Hippo pathway dysfunction who have progressed on prior treatments. Additionally, another Phase 1/2 trial, TEADCO, is underway to evaluate ODM-212 in combination with standard of care therapies for advanced mesothelioma, KRAS G12C mutated non-small cell lung cancer, and pancreatic cancer.

Targeting the Hippo Pathway: ODM-212's Novel Mechanism

Recent research has identified several innovative therapeutic targets that are reshaping treatment approaches for advanced solid tumors. The tumor microbiome has emerged as a particularly compelling target, comprising diverse microbial communities including bacteria, fungi, and viruses within solid tumors. This microbiome modulates tumor cell physiology and immune responses through critical signaling pathways including WNT/β-catenin, NF-κB, toll-like receptors, ERK, and stimulator of interferon genes (STING). The microbiome's regulatory potential extends to genetic abnormalities, epigenetic changes, metabolic regulation, invasion and metastasis, and chronic inflammatory responses, making it an attractive target for personalized cancer treatment approaches.

Novel kinase targets continue to expand the therapeutic landscape, with the FDA authorizing several innovative inhibitors in 2025, including zongeritinib, sunvozertinib, vimseltinib, mirdametinib, avutometinib, and defactinib. Discoidin domain receptor tyrosine kinase 2 (DDR2) has attracted considerable attention due to its involvement in tumor progression and microenvironment remodeling. Additionally, purine-based anticancer agents have broadened their utility in solid tumors by targeting kinases such as CDKs and PI3K, epigenetic regulators like DNMTs, and immune checkpoints, with improved molecular modeling and structure-activity relationships enhancing drug specificity and pharmacokinetics.

Engineered cellular therapies represent another frontier in solid tumor treatment, with CAR-T therapy showing promising clinical potential in gastric cancer, liver cancer, and glioma. CRISPR-edited and off-the-shelf allogeneic CAR-T cells are improving scalability, while AI-driven target discovery, synthetic biology, and cytokine armoring strategies enhance tumor specificity and T-cell persistence. Engineered tumor-infiltrating lymphocyte platforms, including OBX-115 with regulatable membrane-bound IL-15 expression and KSQ-001EX using CRISPR/Cas9 to inactivate SOCS1, are eliminating traditional limitations while maintaining therapeutic efficacy. These advances are complemented by novel T-cell engager targets including STEAP1, MUC16, and PRAME, and innovative combination strategies that integrate multiple therapeutic modalities for enhanced antitumor responses.

Addressing Unmet Needs: ODM-212's Path in Mesothelioma and EHE

Recent literature identifies significant unmet needs in advanced solid tumor management, with particular focus on traditionally underserved populations and emerging therapeutic challenges. These efforts reflect the evolving landscape of precision oncology and the need for more inclusive treatment approaches.

• Heavily pretreated and chemotherapy-resistant populations represent a critical unmet need, with patients who have failed at least two lines of treatment showing poor outcomes and limited therapeutic options

• Elderly patients aged 75 years and older constitute an underserved population with limited evidence-based data regarding immunotherapy efficacy and safety in advanced malignant solid tumors

• Brain metastases management remains a major challenge, affecting up to 40% of individuals with solid tumors, with patients historically excluded from clinical trials despite representing a growing population due to improved survival

• Patients with low or negative PD-L1 expression in advanced solid tumors represent an underserved population, particularly those with esophageal squamous cell carcinoma (TPS < 1%) and HER2-negative gastroesophageal adenocarcinoma (CPS < 5)

• Frail patients with advanced cancer face substantial toxicities from modern treatments including immunotherapy and targeted agents, requiring specialized approaches that balance efficacy with quality of life considerations

• Lymphopenic patients pose a therapeutic challenge as lymphopenia impedes the enduring efficacy of PD-1/PD-L1 inhibitor therapy, with adequate lymphocyte reserves being essential for immunotherapy success

• Rapid progressors at risk of disease progression within 4 months of immunotherapy initiation represent an important population requiring alternative treatment strategies and predictive biomarkers

Early TEAD Inhibitor Success Points to New Avenues in Rare Cancers

The recent Phase 1 data for Orion Pharma's ODM-212, an oral pan-TEAD inhibitor, represents a significant step forward in targeting the Hippo pathway in oncology. This pathway, particularly the YAP/TAZ-TEAD axis, is increasingly recognized as a crucial driver in various cancers, including those with high unmet needs. The early efficacy signals observed in advanced solid tumors, specifically an impressive overall response rate in mesothelioma and epithelioid hemangioendothelioma (EHE), underscore the potential of this therapeutic approach. For patients battling these rare and aggressive cancers, such initial positive data offers a beacon of hope and could pave the way for more targeted and effective treatments.

Strategically, these results position ODM-212 to potentially prioritize development in mesothelioma and EHE, leveraging accelerated regulatory pathways. The drug's oral formulation also offers a practical advantage, enhancing patient convenience. Beyond these specific indications, the success of ODM-212 further validates the Hippo pathway as a critical druggable target, potentially opening doors for its application in other cancers where this pathway is dysregulated, such as papillary renal cell carcinoma and sarcomas. This could also encourage exploration of combination therapies, given the pathway's complex interplay with other oncogenic signals and its role in immune evasion.

However, the journey for TEAD inhibitors is not without its challenges. The Phase 1 data noted proteinuria, and existing literature points to nephrotoxicity as a potential on-target effect of TEAD inhibition. Close monitoring of renal function will be paramount in ongoing and future studies. Furthermore, the development of acquired resistance is a known concern for this class of drugs, suggesting that future treatment paradigms might involve intermittent dosing or combination strategies to sustain long-term efficacy. While these early results are highly encouraging, the transition from promising Phase 1 signals to robust, registrational data in larger patient populations remains a critical hurdle. The continued development of ODM-212 will be closely watched as it navigates these complexities, potentially reshaping treatment landscapes for a range of solid tumors.